Skip to main content
OpenTrials
Completed

NCT Number: NCT03703700

The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET

To explore the application of Zishen Yutai Pill in controlled ovarian stimulation and effect on pregnancy outcome in aged women undergoing in vitro fertilization-embryo transfer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Chongqing Health Center For Women and Children, Chongqing, Chongqing Municipality, China

Loading trial locations.

About this study

This will be a multi-center double-blind randomized controlled trial, which aims to explore the application of Zishen Yutai Pill in controlled ovarian stimulation and effect on pregnancy outcome in aged women undergoing in vitro fertilization-embryo transfer.The target population will be infertile women aged between 35 and 42 years, BMI<28kg/m2 and bilateral ovaries who undergo IVF-ET (long or antagonist protocol). Qualified 1,466 patients are randomized into either of two groups.They will be randomized to receive either Zishen Yutai Pill or the placebo. The pregnancy test results and pregnancy complications will be followed up by checking medical records and telephone calls.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • infertile women aged ≥35 and ≤42 years;
  • intend to undergo IVF/ICSI-ET (GnRH-a long protocol or GnRH-ant protocol);
  • BMI<28kg/m2;
  • bilateral ovaries exist;
  • patients who voluntarily signed the informed consent and agreed to be followed up as required by the study protocol.

Exclusion criteria

  • repeated implantation failure (previous three times or more IVF/ICSI-ET failure);
  • adenomyosis, uterine line constricted by uterine fibroid;
  • untreated bilateral hydrosalpinx;
  • endometrial diseases that have not been cured ;
  • known diseases that are not suitable for undergoing assisted reproductive technology or at the present not suitable for pregnancy;
  • patients who have taken traditional Chinese medicine or Chinese patent medicine for infertility treatment in the last month(30 days).

Exit Criteria:

  • subjects who have adverse events cannot be tolerated;
  • severe breach of the protocol;
  • for subjects who exit due to personal or unpredictable reasons, please describe specific details;
  • subjects considered inappropriate to continue to participate in the study for other medical reasons.

Treatment and study plan

Zishen Yutai Pill

Drug

Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.

Placebo

Drug

Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.

Primary outcomes

  1. Live Birth Rate

    Time frame: 1 year after embryo transfer day, up to a maximum duration of 58 weeks

    Live birth rate=Number of live birth / Paticipants randomized

Secondary outcomes

  1. Number of Retrieved Oocytes

    Time frame: On embryo transfer day, approximately 6 weeks

    The total number of oocytes retrieved through ultrasound-guided transvaginal aspiration.

  2. Rate of Retrieved Oocytes

    Time frame: On embryo transfer day, approximately 6 weeks

    Rate of retrieved oocytes =Number of retrieved oocytes/Number of follicles with a diameter ≥10mm on the HCG injection day.

  3. Number of Matured Oocytes Retrieved

    Time frame: On embryo transfer day, approximately 6 weeks

    The number of oocytes with pronuclei or polar bodies observed on Day 1 after oocyte retrieval in IVF patients, or as the number of MII oocytes on the day of oocyte retrieval in ICSI patients.

  4. Rate of Matured Oocytes

    Time frame: On embryo transfer day, approximately 6 weeks

    Rate of mature oocytes = Number of mature oocytes/Number of retrieved oocytes

  5. Number of Cleavage

    Time frame: On embryo transfer day, approximately 6 weeks

    Number of fertilized oocytes that undergo cleavage on Day 2 after oocyte retrieval.

  6. Cleavage Rate

    Time frame: On embryo transfer day, approximately 6 weeks

    Cleavage rate=Number of all cleaved embryos/Number of fertilized oocytes (2PN+1PN+ multiple PN)

  7. Number of Available Embryos

    Time frame: On embryo transfer day, approximately 6 weeks

    The sum of the number of embryos transferred and the number of embryos frozen.

  8. Rate of Available Embryos

    Time frame: On embryo transfer day, approximately 6 weeks

    Rate of available embryos=Number of available embryos/Number of cleaved oocytes.

  9. Number of High-quality Embryos

    Time frame: On embryo transfer day, approximately 6 weeks

    High-quality embryo will be defined according to the day of embryo transfer, following the Istanbul consensus and Gardner criteria, Day 2: 4 cells, cell fragments <10% and no multi-nucleus; Day 3: 8 cells, cell fragments <10%, no multi-nucleus; Day 5: stage 4 blastocyst, grade A inner cell mass, grade A trophectoderm (12,13).

  10. Rate of High-quality Embryos

    Time frame: On embryo transfer day, approximately 6 weeks

    Rate of high-quality embryos=Number of high-quality embryos/Number of available embryos

  11. Biochemical Pregnancy Rate

    Time frame: 14 days after ET day, approximately 8 weeks

    Biochemical pregnancy rate=Number of positive pregnancy tests/Paticipants randomized

  12. Implantation Rate

    Time frame: five weeks after ET day, approximately 11 weeks

    Implantation rate=Number of gestational sacs/Number of embryos transferred

  13. Clinical Pregnancy Rate

    Time frame: five weeks after ET day, approximately 11 weeks

    The clinical pregnancy determined by the ultrasound, and Clinical pregnancy rate=Number of clinical pregnancies / Paticipants randomized

  14. Miscarriage Rate (Among Positive Pregnancy Test Population)

    Time frame: 1 year after embryo transfer, up to 58 weeks

    Miscarriage Rate (among positive pregnancy test population) =Number of miscarriages / Number of biochemical pregnancy

  15. Miscarriage Rate (Among Clinical Pregnancy Population)

    Time frame: 1 year after embryo transfer, up to 58 weeks

    Miscarriage rate (among clinical pregnancy population)=Number of miscarriages / Number of clinical pregnancies

  16. The Birth Weight of the Newborn

    Time frame: 1 year after embryo transfer, up to 58 weeks

    By checking medical records

  17. The Birth Height of the Newborn

    Time frame: 1 year after embryo transfer, up to 58 weeks

    By checking medical records

  18. Preterm Delivery Among Live Birth

    Time frame: 1 year after embryo transfer, up to 58 weeks

    Delivery of a fetus at less than 37 and more than 28 weeks gestational age.

  19. Low Birth Weight Among Neonates

    Time frame: 1 year after embryo transfer, up to 58 weeks

    Neonatal birth weight ≤ 2500 g.

  20. Congenital Anomalies Among Neonates

    Time frame: 1 year after embryo transfer, up to 58 weeks

    Congenital anomalies are defined as structural or functional anomalies that occur during intrauterine life, including minor and major anomalies.

  21. Neonates Entering NICU

    Time frame: 1 year after embryo transfer, up to 58 weeks

    NICU, neonate intensive care unit.

Sponsors and collaborators

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Other

Registry information

Official study title

The Application of Zishen Yutai Pill in Aged Women Undergoing in Vitro Fertilization-embryo Transfer: a Multi-center Double-blind Randomized Controlled Trial

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Oct 12, 2018
Registry last updated
Mar 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.